Britain and America have established a landmark trade agreement that will ensure zero tariffs on British pharmaceutical products being sold in the American market.
Agreement Details of the Accord
Under the terms of the agreement, the UK has pledged to boost spending on pharmaceuticals through the public health system. This commitment ensures that import taxes on these crucial exports will remain at zero for a timeframe of the next three years.
This agreement comes after recent warnings to hike duties on patented drug products, with figures discussed up to one hundred percent.
"This deal with the Britain reinforces the global environment for cutting-edge drugs and establishes much-needed balance to transatlantic pharmaceutical trade," a statement declared.
Commercial Significance
Pharmaceuticals are one of the Britain's largest exports to the US, which is easily the biggest market for leading UK drugmakers.
Statistics indicate that in the 12 months to the end of the third quarter, the UK shipped drugs worth £11.1bn to the US. This amount made up a significant portion of total UK exports in that period.
"This guarantee safeguards work, stimulates investment and paves the way for the UK to establish itself as a worldwide center for medical research," the Business and Trade Secretary stated.
Key NHS Changes
The pact involves several key changes from the UK:
- Higher Cost Ceiling: The UK will increase the price threshold at which it deems new treatments to be prohibitively costly by twenty-five percent.
- Higher Drug Budget: There is a target to raise overall health service expenditure on drugs from 0.3% of GDP to 0.6% over the coming ten years.
- Refund Ceiling: The amount drug companies must return to the NHS to stay within budget will be capped at 15%. In the past, rebates were more than 20%.
Recent Tensions
The pact comes amid a ongoing row between the drug companies and the British authorities over drug pricing and regulatory access.
The disagreement were heightened by arguments that US customers were paying significantly more for the same drugs than people in the UK and Europe.
Recently, several large pharmaceutical investments in the UK have been delayed or abandoned, while multi-billion-dollar funding commitments have been pledged toward American operations.
One official stated that the NHS must spend more on drugs, noting that its expenditure on drugs had decreased as a share of its resources over the past decade.
